News

Public · Published

Key facts: Hims cuts outlook; adds weight-loss drugs; names Huberman

Hims & Hers reported third-quarter revenue of $890.4 million, up 49% from a year earlier but below estimates, and a $33 million net loss. It cut its 2026 revenue and adjusted EBITDA forecasts, added Eli Lilly weight-loss drugs to its platform, and appointed Andrew Huberman to its board.

Published:

Updated:

What happened

Hims & Hers reported third-quarter revenue of $890.4 million, up 49% from a year earlier but below estimates, and a $33 million net loss. It cut its 2026 revenue and adjusted EBITDA forecasts, added Eli Lilly weight-loss drugs to its platform, and appointed Andrew Huberman to its board.

Confirmed

Global impact / market context

Lower forecasts after revenue missed estimates point to a weaker near-term outlook than the company previously expected. Adding branded weight-loss drugs could support sales, but also makes results depend on access to those medicines and the costs of offering them through its platform.

Analyst inference

The update combines business growth with losses and reduced expectations: revenue rose sharply year over year, yet missed estimates and the company lowered its 2026 outlook. Investors may weigh whether new weight-loss offerings can lift revenue enough to offset costs and improve profit per sale.

Analyst inference

What to watch

  1. Watch for the next reported revenue and net loss, and for any updated 2026 revenue or adjusted EBITDA forecasts that show whether performance is tracking the lower outlook. Analyst inference
  2. Track the rollout and uptake of Zepbound and Foundayo, alongside Ozempic and Wegovy, to see whether branded weight-loss drugs contribute meaningfully to platform sales. Analyst inference
  3. The company plans to launch Peptides+ by late November and expects peptide revenue to be immaterial in Q4; later disclosures can show whether that changes. Confirmed

Evidence

  • Original source link unavailable